To determine the therapeutic potential of PSC-derived myogenic progenitors in FSHD, we took advantage of the iDUX4pA-HSA mouse model referred to above, in which dox treatment allows for the conditional expression of human DUX4 specifically in skeletal muscle22. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.